Abstract
Oral phosphodiesterase inhibitors have become the mainstay of treatment for erectile dysfunction. A novel and potent phosphodiesterase inhibitor, tadalafil, known as Cialis, has been introduced in the UK as an alternative to the other currently available phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Carbolines / administration & dosage*
-
Carbolines / adverse effects
-
Carbolines / pharmacokinetics
-
Clinical Trials, Phase III as Topic
-
Erectile Dysfunction / drug therapy*
-
Humans
-
Male
-
Multicenter Studies as Topic
-
Penile Erection / drug effects
-
Penile Erection / physiology
-
Phosphodiesterase Inhibitors / administration & dosage*
-
Phosphodiesterase Inhibitors / adverse effects
-
Phosphodiesterase Inhibitors / pharmacokinetics
-
Tadalafil
Substances
-
Carbolines
-
Phosphodiesterase Inhibitors
-
Tadalafil